ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacituzumab govitecan

Also written as “Sacituzumab Govitecan-hziy”, “Sacituzumab Govitecan” and “Sacituzumab Govitecan-hziy (SG)”.

Its studies are mostly in Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Transitional Cell · Neoplasm Metastasis, led by 2 companies.

Drug pageSacituzumab govitecan: every studyAll 102 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 19, 202024 company-led studies, 18 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences2317 open or runningphase 4since Mar 19, 2020Jun 26, 2012Dec 2026phase 1 · NCT04617522
Merckits history only11 open or runningphase 3since Nov 2, 2022Nov 2, 2022Jan 12, 2027phase 3 · NCT05609968

Also a collaborator on its studies: Pfizer, Merck KGaA, Darmstadt, Germany and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 8 earlier studies, Jun 26, 2012 to Jun 5, 2020.

  1. Jun 9, 2015Named sacituzumab govitecanINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Aug 19, 2020Phase 3 study in Locally Advanced or Metastatic Unresectable Urothelial CancerNCT04527991 · 711 enrolled · United States, Australia, Austria and more
  3. Nov 2, 2020Phase 1 study in Neoplasm MetastasisNCT04617522 · 30 planned · United States, France, Italy and more
  4. Nov 17, 2020Phase 3 study in Breast NeoplasmsNCT04639986 · 331 enrolled · China, South Korea, Taiwan
  5. Oct 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05089734 · 603 enrolled · United States, Australia, Austria and more
  6. Oct 19, 2021Phase 2 study in Triple Negative Breast NeoplasmsNCT05101096 · 135 enrolled · Japan
  7. Nov 3, 2021Phase 2 study in Solid TumorNCT05119907 · 53 enrolled · China
  8. Dec 23, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05186974 · 193 enrolled · United States, Australia, Canada and more
  9. May 16, 20222 phase 3 studies in Triple Negative Breast NeoplasmsNCT05382299, NCT05382286
  10. Nov 21, 2022Phase 2 study in Lung NeoplasmsNCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
  11. Nov 21, 2022Phase 3 study in Triple Negative Breast NeoplasmsNCT05633654 · 1,514 planned · United States, Australia, Belgium and more
  12. Apr 21, 2023Phase 3 study in Breast NeoplasmsNCT05840211 · 654 enrolled · United States, Argentina, Australia and more
  13. Jun 27, 2024Phase 3 study in Endometrial NeoplasmsNCT06486441 · 640 enrolled · United States, Australia, Brazil and more
  14. Jan 24, 2025Phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT06801834 · 695 planned · United States, Argentina, Australia and more
  15. Apr 8, 2025Phase 2 study in Triple Negative Breast NeoplasmsNCT06926920 · 100 planned · United States, Australia, South Korea

Ahead

  1. Dec 2026Primary completion: phase 3 study in Breast NeoplasmsNCT04639986
  2. Dec 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT04617522
  3. Feb 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT05382286
  4. Mar 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05186974

TargetBeta

TACSTD2 →read by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 23 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06926920Triple Negative Breast Neoplasms · United States, Australia, South Korea2RecruitingJun 2028100
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more3RecruitingOct 2029695
NCT06486441Endometrial Neoplasms · United States, Australia, Brazil and more3Active, not recruitingJun 2029640
NCT05840211Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingApr 2028654
NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more2Active, not recruitingSep 2029192
NCT05633654Triple Negative Breast Neoplasms · United States, Australia, Belgium and more3RecruitingJun 20271,514
NCT05382299Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJul 2028623
NCT05382286Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingFeb 2027443
NCT05186974Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Active, not recruitingMar 2027193
NCT05119907Solid Tumor · China2Active, not recruitingOct 202653
NCT05101096Triple Negative Breast Neoplasms · Japan2Active, not recruitingMay 2027135
NCT05089734Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3Active, not recruitingNov 29, 2023603
NCT04639986Breast Neoplasms · China, South Korea, Taiwan3Active, not recruitingDec 2026331
NCT04617522Neoplasm Metastasis · United States, France, Italy and more1RecruitingDec 202630
NCT04527991Locally Advanced or Metastatic Unresectable Urothelial Cancer · United States, Australia, Austria and more3CompletedJul 4, 2025711
NCT04454437Triple Negative Breast Neoplasms · China2Active, not recruitingAug 6, 202180
NCT04319198Metastatic Solid Tumors · United States, Belgium, France4CompletedOct 18, 202425
NCT03964727Neoplasm Metastasis · United States, Australia, Belgium and more2Active, not recruitingJan 15, 2025227
NCT03901339Breast Neoplasms · United States, Belgium, Canada and more3CompletedOct 20, 2023543
NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more2Active, not recruitingApr 2030502
NCT02574455Breast Neoplasms · United States, Belgium, Canada and more3CompletedMar 30, 2020529
NCT02161679Triple Negative Breast Neoplasms2WithdrawnAug 20160
NCT01631552Esophageal Neoplasms · United States2CompletedMar 1, 2019515

How it is read

Names in the registry

  • “Sacituzumab Govitecan-hziy”, 12 entries
  • “Sacituzumab Govitecan”, 4 entries
  • “Sacituzumab Govitecan-hziy (SG)”, 4 entries
  • “Sacituzumab govitecan-hziy (SG)”, 2 entries
  • “Sacituzumab Govitecan (SG)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.